Elicera Therapeutics Past Earnings Performance
Past criteria checks 0/6
Elicera Therapeutics's earnings have been declining at an average annual rate of -32.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 112.5% per year.
Key information
-32.2%
Earnings growth rate
-23.7%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 112.5% |
| Return on equity | -80.3% |
| Net Margin | -172.2% |
| Next Earnings Update | 29 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Elicera Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 12 | -21 | 34 | 0 |
| 31 Mar 24 | 13 | -20 | 33 | 0 |
| 31 Dec 23 | 11 | -16 | 28 | 0 |
| 30 Sep 23 | 12 | -16 | 28 | 0 |
| 30 Jun 23 | 4 | -18 | 22 | 0 |
| 31 Mar 23 | 2 | -17 | 19 | 0 |
| 31 Dec 22 | 1 | -19 | 21 | 0 |
| 30 Sep 22 | 1 | -18 | 18 | 0 |
| 30 Jun 22 | 0 | -17 | 18 | 0 |
| 31 Mar 22 | 0 | -15 | 16 | 0 |
| 31 Dec 21 | 0 | -13 | 13 | 0 |
| 30 Sep 21 | 0 | -14 | 14 | 0 |
| 30 Jun 21 | 0 | -7 | 7 | 0 |
| 31 Mar 21 | 0 | -5 | 5 | 0 |
| 31 Dec 20 | 0 | -3 | 3 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
| 31 Dec 18 | 0 | 0 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
Quality Earnings: ELIC is currently unprofitable.
Growing Profit Margin: ELIC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ELIC is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.
Accelerating Growth: Unable to compare ELIC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ELIC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: ELIC has a negative Return on Equity (-80.3%), as it is currently unprofitable.